These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15492276)

  • 1. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
    Podar K; Shringarpure R; Tai YT; Simoncini M; Sattler M; Ishitsuka K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
    Cancer Res; 2004 Oct; 64(20):7500-6. PubMed ID: 15492276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
    Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
    Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis.
    Ikeda S; Ushio-Fukai M; Zuo L; Tojo T; Dikalov S; Patrushev NA; Alexander RW
    Circ Res; 2005 Mar; 96(4):467-75. PubMed ID: 15692085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
    Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
    Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site.
    Wallez Y; Cand F; Cruzalegui F; Wernstedt C; Souchelnytskyi S; Vilgrain I; Huber P
    Oncogene; 2007 Feb; 26(7):1067-77. PubMed ID: 16909109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caveolin-1 as a potential new therapeutic target in multiple myeloma.
    Podar K; Anderson KC
    Cancer Lett; 2006 Feb; 233(1):10-5. PubMed ID: 16473666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells.
    Wickström SA; Alitalo K; Keski-Oja J
    Cancer Res; 2002 Oct; 62(19):5580-9. PubMed ID: 12359771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
    Koldehoff M; Beelen DW; Elmaagacli AH
    J Leukoc Biol; 2008 Aug; 84(2):561-76. PubMed ID: 18458152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
    Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
    Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
    Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
    Moschetta M; Di Pietro G; Ria R; Gnoni A; Mangialardi G; Guarini A; Ditonno P; Musto P; D'Auria F; Ricciardi MR; Dammacco F; Ribatti D; Vacca A
    Eur J Cancer; 2010 Jan; 46(2):420-9. PubMed ID: 19914061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.
    Vincent L; Jin DK; Karajannis MA; Shido K; Hooper AT; Rashbaum WK; Pytowski B; Wu Y; Hicklin DJ; Zhu Z; Bohlen P; Niesvizky R; Rafii S
    Cancer Res; 2005 Apr; 65(8):3185-92. PubMed ID: 15833849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
    Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
    Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis.
    Sanda T; Kuwano T; Nakao S; Iida S; Ishida T; Komatsu H; Shudo K; Kuwano M; Ono M; Ueda R
    Leukemia; 2005 Jun; 19(6):901-9. PubMed ID: 15843826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.